Subscribe
shutterstock_1017347380_sundryphotography
sundryphotography / Shutterstock.com
24 September 2020AmericasSarah Morgan

Genmab locked in J&J royalty payments dispute

Danish biotech Genmab has commenced binding arbitration of two matters with Janssen Biotech, a Johnson & Johnson company, over royalty payments for a cancer drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
J&J, HHS sign expanded deal to find COVID-19 vaccine
14 February 2020   Johnson & Johnson unit Janssen has expanded an existing R&D agreement with the US Department of Health and Human Services (HHS) as part of efforts to speed up the development of an investigational vaccine for the novel coronavirus COVID-19.
Americas
J&J announces $6.5bn Momenta acquisition, days after Sanofi deal
20 August 2020   Johnson & Johnson is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments.
Medtech
Conformis launches implant lawsuit against J&J subsidiary
4 May 2021   US medtech company Conformis has filed a lawsuit against J&J Medical Devices-owned DePuy Synthes, alleging that it infringed on its custom implant and surgery software patents.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
J&J, HHS sign expanded deal to find COVID-19 vaccine
14 February 2020   Johnson & Johnson unit Janssen has expanded an existing R&D agreement with the US Department of Health and Human Services (HHS) as part of efforts to speed up the development of an investigational vaccine for the novel coronavirus COVID-19.
Americas
J&J announces $6.5bn Momenta acquisition, days after Sanofi deal
20 August 2020   Johnson & Johnson is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments.
Medtech
Conformis launches implant lawsuit against J&J subsidiary
4 May 2021   US medtech company Conformis has filed a lawsuit against J&J Medical Devices-owned DePuy Synthes, alleging that it infringed on its custom implant and surgery software patents.

More on this story

Big Pharma
J&J, HHS sign expanded deal to find COVID-19 vaccine
14 February 2020   Johnson & Johnson unit Janssen has expanded an existing R&D agreement with the US Department of Health and Human Services (HHS) as part of efforts to speed up the development of an investigational vaccine for the novel coronavirus COVID-19.
Americas
J&J announces $6.5bn Momenta acquisition, days after Sanofi deal
20 August 2020   Johnson & Johnson is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments.
Medtech
Conformis launches implant lawsuit against J&J subsidiary
4 May 2021   US medtech company Conformis has filed a lawsuit against J&J Medical Devices-owned DePuy Synthes, alleging that it infringed on its custom implant and surgery software patents.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent